Cyanoacrylates are fast-acting adhesives used in procedural medicine including closure of superficial wounds, embolization of truncal vessels pre-operatively, vascular anomalies, visceral false aneurysms, endoleaks, gastrointestinal varices and gastrointestinal bleeding. More recently, catheter-directed cyanoacrylate adhesive closure was introduced as an alternative to endovenous thermal ablation (ETA) to occlude superficial veins of the lower limbs.
Objectives
To formulate policies for the safe and effective delivery of cyanoacrylate adhesive closure procedures in Australasia, based on current experience and evidence.
Methods
A panel of phlebologists including vascular surgeons, interventional radiologists, dermatologists and research scientists systematically reviewed the available data on cyanoacrylate products used in medicine and shared personal experience with the procedure. The reviewed material included bibliographic and biomedical data, material safety data sheets and data requested and received from manufacturers.
Results and recommendations: Cyanoacrylate adhesive closure appears to be an effective treatment for saphenous reflux with occlusion rates at 36 months of 90–95%. We recommend a maximum dose of 10 mL of cyanoacrylate per treatment session. Serious complications are rare, but significant. Hypersensitivity to acrylates is reported in 2.4% of the population and is an important absolute contraindication to cyanoacrylate adhesive closure.1 Post-procedural inflammatory reactions, including hypersensitivity-type phlebitis, occur in 10–20% of patients.2 In the long term, cyanoacrylate adhesive closure results in foreign-body granuloma formation within 2–12 months of the procedure. We recommend against the use of cyanoacrylate adhesive closure in patients with uncontrolled inflammatory, autoimmune or granulomatous disorders (e.g. sarcoidosis). Caution should be exercised in patients with significant active systemic disease or infection and alternative therapies such as thermal ablation and foam sclerotherapy should be considered.
Conclusions
Cyanoacrylate adhesive closure appears to be an effective endovenous procedure, with short-term closure rates comparable to ETA and therefore greater efficacy than traditional surgery for treating superficial veins of the lower limbs. Ongoing data collection is required to establish the long-term safety.
RosenRJContractorS.The use of cyanoacrylate adhesives in the management of congenital vascular malformations.Semin Intervent Radiol2004;
21: 59–66.
5.
MattamalGJ.US FDA perspective on the regulations of medical-grade polymers: cyanoacrylate polymer medical device tissue adhesives.Expert Rev Med Devices2008;
5: 41–49.
6.
U.S. Food and Drug Administration Center for Devices and Radiologic Health. TRUFILL® n-Butyl cyanoacrylate (n-BCA) liquid embolic system – P990040. USA: U.S. Food and Drug Administration Center for Devices and Radiologic Health, 2000.
U.S. Food and Drug Administration Center for Devices and Radiologic Health. VenaSeal closure system – P140018. USA: U.S. Food and Drug Administration Center for Devices and Radiologic Health, 2015.
10.
Tang TY, Rathnaweera HP, Kam JW, et al. Endovenous cyanoacrylate glue to treat varicose veins and chronic venous insufficiency-Experience gained from our first 100+ truncal venous ablations in a multi-ethnic Asian population using the Medtronic VenaSeal Closure System. Phlebology. 2019; 34: 543–551.
11.
Australian Government, Department of Health Therapeutic Goods Administration. 158438 Matrix Surgical Pty Ltd – GLUBRAN 2 – multi-purpose surgical adhesive. Australia: Australian Government, Department of Health Therapeutic Goods Administration, 2009.
12.
LoffroyR.Glubran2®, Histoacryl® or Trufill®: which cyanoacrylate glue for endovascular use?Diagn Interv Imaging2016;
97: 119.
13.
Australian Government, Department of Health Therapeutic Goods Administration. 206441 B Braun Australia Pty Ltd – histoacryl – adhesive, soft tissue approximation. Australia: Australian Government, Department of Health Therapeutic Goods Administration, 2013.
14.
BracardSMacHo-FernándezJMWangX, et al.
Influence of temperature on embolisation with cyanoacrylate.Interv Neuroradiol1998;
4: 301–305.
15.
U.S. Food and Drug Administration Center for Devices and Radiologic Health. Histoacryl and Histoacryl Blue – P050013. USA: U.S. Food and Drug Administration Center for Devices and Radiologic Health, 2007.
16.
Australian Government Department of Health Therapeutic Goods Administration. 283083 Surgical Specialties Pty Ltd – adhesive, soft tissue approximation. Australia: Australian Government Department of Health Therapeutic Goods Administration, 2016.
17.
ChalmersBPMeluginHPSculcoPK, et al.
Characterizing the diagnosis and treatment of allergic contact dermatitis to 2-octyl cyanoacrylate used for skin closure in elective orthopedic surgery.J Arthroplasty2017;
32: 3742–3747.
18.
PollakJSWhiteRIJr.The use of cyanoacrylate adhesives in peripheral embolization.J Vasc Interv Radiol2001;
12: 907–913.
19.
KitagawaAYamamotoTMatsunagaN, et al.
Polidocanol sclerotherapy combined with transarterial embolization using n-butyl cyanoacrylate for extracranial arteriovenous malformations.Cardiovasc Interv Radiol2018;
41: 856–866.
20.
TakeuchiYMorishitaHSatoY, et al.
Guidelines for the use of NBCA in vascular embolization devised by the Committee of Practice Guidelines of the Japanese Society of Interventional Radiology (CGJSIR), 2012 edition.Jpn J Radiol2014;
32: 500–517.
21.
ShaidakovEVMel’tsovaAZPorembskaiaOI, et al.
Experience with using cyanoacrylate glue in endovascular treatment of varicose veins.Angiologiia i sosudistaia khirurgiia (Angiol Vasc Surg)2017;
23: 62–67.
22.
ParsiKKangMYangA, et al. Granuloma formation following cyanoacrylate glue injection in peripheral veins and arteriovenous malformation. Phlebology. 2020; 35:115–123.
23.
GruberAMazalPRBavinzskiG, et al.
Repermeation of partially embolized cerebral arteriovenous malformations: a clinical, radiologic, and histologic study. AJNR AM J Neuroradiol1996;
17: 1323–1331.
24.
BrothersMFKaufmannJCFoxAJ, et al.
n-Butyl 2-cyanoacrylate – substitute for IBCA in interventional neuroradiology: histopathologic and polymerization time studies.AJNR Am J Neuroradiol1989;
10: 777–786.
25.
MazalPRStichenwirthMGruberA, et al.
Tissue reactions induced by different embolising agents in cerebral arteriovenous malformations: a histopathological follow-up.Pathology2006;
38: 28–32.
26.
QuinnJCMittalNBaisreA, et al.
Vascular inflammation with eosinophils after the use of n-butyl cyanoacrylate liquid embolic system.J Neurointerv Surg2011;
3: 21–24.
27.
MinRJAlmeidaJIMcLeanDJ, et al.
Novel vein closure procedure using a proprietary cyanoacrylate adhesive: 30-day swine model results.Phlebology2012;
27: 398–403.
28.
AlmeidaJIMinRJRaabeR, et al.
Cyanoacrylate adhesive for the closure of truncal veins: 60-day swine model results.Vasc Endovasc Surg2011;
45: 631–635.
KorkmazÖGökselSGülM, et al.
Does the use of N-butyl-2 cyanoacrylate in the treatment of lower extremity superficial varicose veins cause acute systemic inflammation and allergic reactions?Cardiovasc J Africa 2018; 29: 213–217.
31.
GibsonKFerrisB.Cyanoacrylate closure of incompetent great, small and accessory saphenous veins without the use of post-procedure compression: initial outcomes of a post-market evaluation of the VenaSeal System (the WAVES Study).Vascular2017;
25: 149–156.
32.
ParkIJeongMHParkCJ, et al.
Clinical features and management of “phlebitis-like abnormal reaction” after cyanoacrylate closure for the treatment of incompetent saphenous veins.Ann Vasc Surg 2019; 55: 239–245.
33.
YacoubM-RLemièreCMaloJ-L.Asthma caused by cyanoacrylate used in a leisure activity.J Allergy Clin Immunol2005;
116: 462.
WattsTJThursfieldDHaqueR. Allergic contact dermatitis due to VenaSeal tissue adhesive. Contact Dermatitis 2019; 80: 393–395.
36.
SassevilleD.Acrylates in contact dermatitis. Dermatitis2012;
23: 6–16.
37.
PiiriläPKanervaLKeskinenH, et al.
Occupational respiratory hypersensitivity caused by preparations containing acrylates in dental personnel. Clin Exp Allergy1998;
28: 1404–1411.
38.
MestachLHuygensSGoossensA, et al.
Allergic contact dermatitis caused by acrylic-based medical dressings and adhesives. Contact Dermatitis2018;
79: 81–84.
39.
MoseKFAndersenKEChristensenLP.Stability of selected volatile contact allergens in different patch test chambers under different storage conditions.Contact Dermatitis2012;
66: 172–179.
40.
ScolaroRJCrillyHMMaycockEJ, et al.
Australian and New Zealand anaesthetic allergy group perioperative anaphylaxis investigation guidelines.Anaesth Intensive Care2017;
45: 543–555.
41.
KoppulaSVFellmanJHStorrsFJ.Screening allergens for acrylate dermatitis associated with artificial nails.Am J Contact Dermatitis1995;
6: 78–85.
42.
TsengYMaLLuoT, et al.
Thromboembolic events secondary to endoscopic cyanoacrylate injection: can we foresee any red flags?Can J Gastroenterol Hepatol2018;
2018: 1940592.
43.
United States Department of Health and Human Services, National Toxicology Program, www.ntp.niehs.nih.gov/ (accessed 10 December 2018).
44.
ChenWLLinCTHsiehCY, et al.
Comparison of the bacteriostatic effects, corneal cytotoxicity, and the ability to seal corneal incisions among three different tissue adhesives. Cornea2007;
26: 1228–1234.
45.
de Almeida ManzanoRPNaufalSCHidaRY, et al.
Antibacterial analysis in vitro of ethyl-cyanoacrylate against ocular pathogens. Cornea2006;
25: 350–351.
RomeroILMaltaJBNSSilvaCB, et al.
Antibacterial properties of cyanoacrylate tissue adhesive: does the polymerization reaction play a role?Indian J Ophthalmol2009;
57: 341–344.
48.
EifermanRASnyderJW.Antibacterial effect of cyanoacrylate glue.Arch Ophthalmol1983;
101: 958–960.
49.
AlmeidaJIJavierJJMackayEG, et al.
Three-year follow-up of first human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence.J Vasc Surg Venous Lymphat Disord2015;
3: 125.
50.
AlmeidaJIJavierJJMackayEG, et al.
Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence.J Vasc Surg Venous Lymphat Disorders2017;
5: 658–2.
51.
ProebstleTMAlmJDimitriS, et al.
Twelve-month follow-up of the European multicenter study on cyanoacrylate embolization of incompetent great saphenous veins.J Vasc Surg Venous Lymphat Disord2014;
2: 105–2.
52.
TekinAİTuncerONMemetoğluME, et al.
Nonthermal, nontumescent endovenous treatment of varicose veins.Ann Vascul Surg2016;
36: 231–2.
53.
YasimAErogluEBozoglanO, et al.
A new non-tumescent endovenous ablation method for varicose vein treatment: early results of N-butyl cyanoacrylate (VariClose®).Phlebology2016;
32: 194–199.
54.
ChanYCLawYCheungGC, et al.
Cyanoacrylate glue used to treat great saphenous reflux: measures of outcome.Phlebology2017;
32: 99–106.
55.
ToonderIMLamYLLawsonJ, et al.
Cyanoacrylate adhesive perforator embolization (CAPE) of incompetent perforating veins of the leg, a feasibility study.Phlebology2014;
29: 49–54.
56.
BozkurtAKYilmazMF.A prospective comparison of a new cyanoacrylate glue and laser ablation for the treatment of venous insufficiency.Phlebology2016;
31: 106–113.
57.
ErogluEYasimA.A randomised clinical trial comparing n-butyl cyanoacrylate, radiofrequency ablation and endovenous laser ablation for the treatment of superficial venous incompetence: two year follow up results.Eur J Vasc Endovasc Surg2018;
56: 553–560.
58.
MontgomeryRStocksSJWilkinsonSM.Contact allergy resulting from the use of acrylate nails is increasing in both users and those who are occupationally exposed.Contact Dermatitis2016;
74: 120–122.
59.
AndujarRCruzMJVillarA, et al.
High eosinophil levels and poor evolution in occupational asthma due to cyanoacrylate exposure.Am J Ind Med2011;
54: 714–718.
60.
SinhaKRDuckwilerGRootmanDB.Urticarial reaction following endovascular embolization of an orbital arteriovenous malformation (AVM) with n-butyl cyanoacrylate (nBCA) glue.Interv Neuroradiol2017;
23: 666–668.
61.
Gatica-OrtegaMEPastor-NietoMASilvestre-SalvadorJF.Allergic contact dermatitis caused by acrylates in long-lasting nail polish.Actas dermo-sifiliograficas2018;
109: 508–2.
62.
LazarovA.Sensitization to acrylates is a common adverse reaction to artificial fingernails.J Eur Acad Dermatol Venereol2007;
21: 169–174.
63.
RaposoILoboIAmaroC, et al.
Allergic contact dermatitis caused by (meth)acrylates in nail cosmetic products in users and nail technicians – a 5-year study. Contact Dermatitis2017;
77: 356–2.
64.
LindströmMAlankoKKeskinenH, et al.
Dentist’s occupational asthma, rhinoconjunctivitis, and allergic contact dermatitis from methacrylates.Allergy2002;
57: 543–2.
65.
AlmeidaJIJavierJJMackayEG, et al.
Two-year follow-up of first human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence.Phlebology2015;
30: 397–404.
66.
KolluriRGibsonKCherD, et al.
Roll-in phase analysis of clinical study of cyanoacrylate closure for incompetent great saphenous veins.J Vasc Surg Venous Lymphat Disord2016;
4: 407–2.
67.
KoramazİEl KılıçHGökalpF, et al.
Ablation of the great saphenous vein with nontumescent n-butyl cyanoacrylate versus endovenous laser therapy.J Vasc Surg Venous Lymphat Disord2017;
5: 210–2.
68.
ParkI.Initial outcomes of cyanoacrylate closure, venaseal system, for the treatment of the incompetent great and small saphenous veins.Vasc Endovasc Surgery2017;
51: 545–549.
69.
YavuzTAcarANAydınH, et al.
A retrospective study of a new n-butyl-2-cyanoacrylate glue ablation catheter incorporated with application guiding light for the treatment of venous insufficiency: twelve-month results.Vascular2018;
26: 547–555.
70.
ProebstleTMAlmJDimitriS, et al.
The European multicenter cohort study on cyanoacrylate embolization of refluxing great saphenous veins.J Vasc Surg Venous Lymphat Disord2015;
3: 2–7.
71.
LawsonJGauwSvan VlijmenC, et al.
Sapheon: the solution?Phlebology2013;
28: 2–9.
72.
ZierauU-T.Results for 795 treated truncal veins after 1000 days. Vasomed2015;
3: 124–128.
73.
ZernovickyF.Fast progressive devastating granulomatic reaction after VenaSeal procedure. Int Angiol2018;
37: S168–S169.
74.
LamYLDe MaeseneerMLawsonJ, et al.
Expert review on the VenaSeal(R) system for endovenous cyano-acrylate adhesive ablation of incompetent saphenous trunks in patients with varicose veins.Expert Rev Med Dev2017;
14: 755–762.
75.
PillutlaAHendrixMPHaJ. Endovenous glue-induced thrombosis in nonthermal glue closure therapy for greater saphenous vein insufficiency: a single-center experience. J Vasc Interv Radiol 2019; 30: 1075–1080.
76.
AlmeidaJIJavierJJMackayEG, et al.
Thirty-sixth-month follow-up of first-in-human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence.J Vasc Surg Venous Lymphat Disord2017;
5: 658–666.
77.
ParaskevasP. Deep venous complications following cyanoacrylate embolisation. In: 20th annual scientific meeting and workshops of the Australasian College of Phlebology, Cairns, Australia, 7 May 2019.
78.
TissueSeal. Histoacryl® and histoacryl® blue topical skin adhesive foil pouch packaging (package insert).
USA:
TissueSeal, 2008.
79.
AbbarBVimpereDKhaterS, et al.
Cerebral infarction following cyanoacrylate endoscopic therapy of duodenal varices in a patient with a patent foramen ovale.Internal Emerg Med2018;
13: 817–819.
80.
HillHChickJFBHageA, et al.
N-butyl cyanoacrylate embolotherapy: techniques, complications, and management.Diagn Interv Radiol2018;
24: 98–103.
81.
ChalmersBPMeluginHPSculcoPK, et al.
Characterizing the diagnosis and treatment of allergic contact dermatitis to 2-octyl cyanoacrylate used for skin closure in elective orthopedic surgery.J Arthroplasty2017;
32: 3742–3747.
82.
LakeNHBarlowBTToledanoJE, et al.
Contact dermatitis reaction to 2-octyl cyanoacrylate following 3 orthopedic procedures.Orthopedics2018;
41: e289–e291.
83.
ArnoldussenCWde GraafRWittensCH, et al.
Value of magnetic resonance venography and computed tomographic venography in lower extremity chronic venous disease.Phlebology2013;
28: 169–175.
84.
NesbittCBedenisRBhattacharyaV, et al.
Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus open surgery for great saphenous vein varices.Cochrane Database Systematic Rev2014:
7: Cd005624.
85.
NICE guidelines. Varicose veins: diagnosis and management, www.nice.org.uk/guidance/cg168 (2013, accessed 22 November 2018).
86.
MarsdenGPerryMKelleyK, et al.
Diagnosis and management of varicose veins in the legs: summary of NICE guidance.BMJ 2013; 347: f4279.
87.
GloviczkiPComerotaAJDalsingMC, et al.
The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum.J Vasc Surg2011;
53: 2s–48s.
88.
NICE guidelines. Cyanoacrylate glue occlusion for varicose veins, www.nice.org.uk/guidance/ipg526 (2015, accessed 11 March 2019).
89.
CapriniJA.Thrombosis risk assessment as a guide to quality patient care.Dis Mon2005;
51: 70–78.
90.
MatarL.Direct injection of cyanoacrylate into perforators (DICAP). Int Angiol2018;
37: S76.
